An NCI-designated Comprehensive Cancer Center
Shai Izraeli - Systems Biology

Shai Izraeli, M.D.

Research Professor, Department of Systems Biology
Research Focus
  • Hematologic malignancies
  • Cancer predisposition syndromes
  • Centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer
Contact
Email: [email protected]

Research Teams

  • Systems Biology
I am a physician-scientist that focuses on translational laboratory-based cancer research with a particular emphasis on hematological malignancies and on cancer predisposition syndromes. Another major research interest is centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer. These two interests are merged in the study of leukemias associated with germline aneuploidy (Down Syndrome).
 
We combine advanced genomic approaches with functional pre-clinical models. Several of our discoveries proved to be of general importance to children and adults with acute leukemias. These include the discovery of ERG as an important hematopoietic oncogene, in addition to its known role in prostate cancer, and the discoveries of unique activating JAK2 mutations and of mutational activation of the cytokine receptors to TSLP and interleukin 7 in acute lymphoblastic leukemias (ALL).
 
These findings have led to new diagnostic tests and clinical trials of ALL in adult and children. Our more general cancer-aneuploidy and centrosomal biology research has been promoted by our discovery of STIL (previously named SIL), a gene disrupted in T-ALL, is a major centrosomal duplication factor in mammalian cells. We study how STIL, centrosomes and the hedgehog pathway are involved in development and cancer. We are developing novel therapeutics targeting the STIL pathways for epithelial cancers, for example ovarian cancer. This line of research reflects the integrative nature of current cancer research focusing on biological processes in addition to specific types of cancers.
 
Our research of Down Syndrome and of STIL (that is involved in autosomal recessive microcephaly) have led me to further develop my research interest in congenital and hereditary disorders predisposing to cancer. Germline variants are increasingly recognized as key players in cancer. We are currently studying human pedigrees and creating mouse models of such germline driven disorders. These studies have been funded by multiple national and international grants and have involved multiple national and international collaborations in both basic and clinical research with scientists and clinicians in North America, Australia, Japan and Europe.
 

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Kratz, C. P. and S. Izraeli. "Down Syndrome, Rasopathies, and Other Rare Syndromes." Semin Hematol 54, no. 2 (Apr 2017): 123-28 
  • Savino, A. M. and S. Izraeli. "Interleukin-7 Signaling as a Therapeutic Target in Acute Lymphoblastic Leukemia." Expert Rev Hematol 10, no. 3 (Mar 2017): 183-85. 
  • Frishman-Levy, L. and S. Izraeli, Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. Br J Haematol, 2017. 176(2): p. 157-167. 
  • Ofran, Y. and S. Izraeli, BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options. Blood Rev, 2017. 31(2): p. 11-16 
  • Izraeli, S., The acute lymphoblastic leukemia of Down Syndrome - Genetics and pathogenesis. Eur J Med Genet, 2016. 59(3): p. 158-61. 
  • Savino, A.M. and S. Izraeli, On mice and humans: the role of thymic stromal lymphopoietin in human B-cell development and leukemia. Haematologica, 2016. 101(4): p. 391-3. 
  • Pui, C.H., J.J. Yang, S.P. Hunger, R. Pieters, M. Schrappe, A. Biondi, A. Vora, A. Baruchel, L.B. Silverman, K. Schmiegelow, G. Escherich, K. Horibe, Y.C. Benoit, S. Izraeli, A.E. Yeoh, D.C. Liang, J.R. Downing, W.E. Evans, M.V. Relling, and C.G. Mullighan, Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol, 2015. 33(27): p. 2938-48. 
  • Tal, N., C. Shochat, I. Geron, D. Bercovich, and S. Izraeli, Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cell Mol Life Sci, 2014. 71(3): p. 365-78. 
  • Roberts, I. and S. Izraeli, Haematopoietic development and leukaemia in Down syndrome. Br J Haematol, 2014. 10.1111/bjh.13096. 
  • Mezei, G., M. Sudan, S. Izraeli, and L. Kheifets, Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol, 2014. 10.1016/j.canep.2014.07.006. 
  • Izraeli, S., A. Vora, C.M. Zwaan, and J. Whitlock, How I treat ALL in Down's syndrome: pathobiology and management. Blood, 2014. 123(1): p. 35-40. 
  • Izraeli, S., C. Shochat, N. Tal, and I. Geron, Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia. Cancer Lett, 2014. 10.1016/j.canlet.2014.02.009. 
  • Izraeli, S., Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises. Curr Opin Hematol, 2014. 21(4): p. 289-96. 
  • Birger, Y. and S. Izraeli, DYRK1A in Down syndrome: an oncogene or tumor suppressor? J Clin Invest, 2012. 122(3): p. 807-10. 
  • Izraeli, S., Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol, 2010. 151(2): p. 119-31. 
  • Bourquin, J.P. and S. Izraeli, Where can biology of childhood ALL be attacked by new compounds? Cancer Treat Rev, 2010. 36(4): p. 298-306. 
  • Ganmore, I., G. Smooha, and S. Izraeli, Constitutional aneuploidy and cancer predisposition. Hum Mol Genet, 2009. 18(R1): p. R84-93. 
  • Izraeli, S., L. Rainis, L. Hertzberg, G. Smooha, and Y. Birger, Trisomy of chromosome 21 in leukemogenesis. Blood Cells, Molecules, and Diseases, 2007. 39(2): p. 156-159. 
  • Izraeli, S., Down's syndrome as a model of a pre-leukemic condition. Haematologica, 2006. 91(11): p. 1448-52. 
  • Izraeli, S., Perspective: chromosomal aneuploidy in leukemia--lessons from down syndrome. Hematol Oncol, 2006. 24(1): p. 3-6. 
  • Izraeli, S., Chromosome copy number and leukemia-lessons from Down's syndrome. Hematology, 2005. 10 Suppl 1: p. 164-6. 
  • Somech, R., S. Izraeli, and J.S. A, Histone deacetylase inhibitors--a new tool to treat cancer. Cancer Treat Rev, 2004. 30(5): p. 461-72. 
  • Izraeli, S. and D. Waldman, Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. Acta Haematol, 2004. 112(1-2): p. 34-9. 
  • Izraeli, S., Leukaemia -- a developmental perspective. Br J Haematol, 2004. 126(1): p. 3-10. 
  • Izraeli, S., Congenital syndromes and leukemia: clues to pathogenesis. Rev Clin Exp Hematol, 2003. 7(3): p. 246-60. 
  • Izraeli, S., I. Witz, and M. Micksche, Cancer research--from bench to bedside. Isr Med Assoc J, 2002. 4(9): p. 746-8. 
  • Izraeli, S. and G. Rechavi, Molecular medicine--an overview. Isr Med Assoc J, 2002. 4(8): p. 638-40. 
  • Izraeli, S., A. Rachmel, and M. Nitzan, [Vestibular dysfunction and deafness complicating mumps parotitis]. Harefuah, 1989. 117(9): p. 243-4. 
  • Izraeli, S., A. Israeli, and Y. Danon, [Pharmacological treatment of cyanide poisoning]. Harefuah, 1988. 114(7): p. 338-42. 
In The News